中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.021 seconds)

    Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy
    3.
    发明申请
    Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy 审中-公开
    联合治疗用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡聚糖化合物治疗肝炎病毒感染的方法

    公开(公告)号：US20060106065A1

    公开(公告)日：2006-05-18

    申请号：US11300463

    申请日：2005-12-15

    Applicant: Gary Jacob ,  Timothy Block ,  Raymond Dwek

    Inventor： Gary Jacob ,  Timothy Block ,  Raymond Dwek

    IPC: A61K31/445

    CPC classification number: C07D211/46 ,  A61K31/445 ,  A61K45/06

    Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

    Abstract translation: 提供用于治疗哺乳动物，特别是人类的肝炎病毒感染的方法和组合物。 方法包括（1）与核苷抗病毒剂，核苷酸抗病毒剂，其混合物或免疫调节/免疫刺激剂组合施用N-取代的-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物，或（2 ）与核苷抗病毒剂，核苷酸抗病毒剂或其混合物以及免疫调节/免疫刺激剂组合施用N-取代的-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物。

    Method and system for filtering inter-node communication in a data processing system
    4.
    发明申请
    Method and system for filtering inter-node communication in a data processing system 失效
    用于过滤数据处理系统中节点间通信的方法和系统

    公开(公告)号：US20050025122A1

    公开(公告)日：2005-02-03

    申请号：US10933599

    申请日：2004-09-03

    Applicant: Timothy Block ,  Richard Booth ,  David Engebretsen ,  Thomas Sand ,  Kenneth Valk

    Inventor： Timothy Block ,  Richard Booth ,  David Engebretsen ,  Thomas Sand ,  Kenneth Valk

    IPC: H04L12/56 ,  H04L12/28

    CPC classification number: H04L49/351 ,  H04L49/3009

    Abstract: A method and system for communication in a system area network (SAN) data processing system are described. The SAN includes a plurality of interconnected nodes that each have at least one port for communication. To avoid communication-induced errors that may arise, for example, if multiple nodes share the same node ID, the port of a node in the SAN is marked as “fenced” to prevent transmission of packets of a first traffic type while permitting transmission of packets of a second traffic type. The marking of the port may be recorded, for example, in a configuration register of the port. While the port is fenced, only packets of other than the first traffic type are routed via the port. In one preferred embodiment, the second traffic type represents SAN configuration traffic, and the first traffic type represents non-configuration traffic. In this preferred embodiment, the marking of the port may be removed following communication of configuration traffic utilized to negotiate unique node ID throughout the SAN.

    Abstract translation: 描述了系统区域网（SAN）数据处理系统中的通信方法和系统。 SAN包括多个互连的节点，每个节点具有至少一个用于通信的端口。 为了避免可能出现的通信引起的错误，例如，如果多个节点共享相同的节点ID，则SAN中的节点的端口被标记为“围栏”，以防止第一业务类型的分组的传输，同时允许 第二种流量类型的数据包。 端口的标记可以记录在例如端口的配置寄存器中。 当端口被隔离时，只有除第一个流量类型之外的数据包通过端口路由。 在一个优选实施例中，第二流量类型表示SAN配置流量，第一流量类型表示非配置流量。 在该优选实施例中，可以在通过用于在整个SAN中协商唯一节点ID的配置流量通信之后去除端口的标记。

    IDENTIFICATION OF MODULATORS OF SERINE PROTEASE INHIBITOR KAZAL AND THEIR USE AS ANTI-CANCER AND ANTI-VIRAL AGENTS
    5.
    发明申请
    IDENTIFICATION OF MODULATORS OF SERINE PROTEASE INHIBITOR KAZAL AND THEIR USE AS ANTI-CANCER AND ANTI-VIRAL AGENTS 审中-公开
    丝氨酸蛋白酶抑制剂KAZAL调节剂的鉴定及其作为抗癌剂和抗病毒剂的用途

    公开(公告)号：US20120244160A1

    公开(公告)日：2012-09-27

    申请号：US13480886

    申请日：2012-05-25

    Applicant: Xuanyong Lu ,  Timothy Block

    Inventor： Xuanyong Lu ,  Timothy Block

    IPC: A61K31/713 ,  C12Q1/02 ,  C07H21/02 ,  C07K16/40 ,  A61K39/395 ,  C40B30/08 ,  C12Q1/68

    CPC classification number: C12Q1/37 ,  G01N2333/96433 ,  G01N2500/02

    Abstract: This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

    Abstract translation: 本公开描述了癌症的相关病因和新型抗癌治疗策略，基于以下发现：称为丝氨酸蛋白酶抑制剂（SPIK / SPINK / PSTI）的蛋白质被乙型和丙型肝炎病毒感染上调，从而抑制细胞 凋亡。 因此，本公开尤其提供SPIK抑制剂和/或抑制细胞中SPIK过度表达的技术。 抑制剂包括：1）可抑制SPIK转录物，蛋白质活性和基因表达的化合物，2）SPIK siRNA（SPIK的RNAi基因沉默或dsRNA，3）DNA反义和抗SPIK抗体。 此外，本公开提供使用抑制剂作为抗癌剂来重新制备癌细胞凋亡（例如，丝氨酸蛋白酶依赖性细胞凋亡）的方法。

    Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
    6.
    发明授权
    Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents 失效
    鉴定丝氨酸蛋白酶抑制剂Kazal的调节剂及其作为抗癌和抗病毒剂的用途

    公开(公告)号：US08193328B2

    公开(公告)日：2012-06-05

    申请号：US12065840

    申请日：2006-09-07

    Applicant: Xuanyong Lu ,  Timothy Block

    Inventor： Xuanyong Lu ,  Timothy Block

    IPC: C12N15/15 ,  C12N15/11 ,  C12N15/113

    CPC classification number: C12Q1/37 ,  G01N2333/96433 ,  G01N2500/02

    Abstract: This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

    Abstract translation: 本发明描述了癌症的相关病因和新型抗癌治疗策略，基于以下发现：称为丝氨酸蛋白酶抑制剂（SPIK / SPINK / PSTI）的蛋白质被乙型和丙型肝炎病毒感染上调，从而抑制细胞 凋亡。 因此，本发明提供了SPIK抑制剂和/或抑制细胞中SPIK过度表达的技术。 抑制剂包括：1）可抑制SPIK转录物，蛋白质活性和基因表达的化合物，2）SPIK siRNA（SPIK的RNAi基因沉默或dsRNA，3）DNA反义和抗SPIK抗体。 此外，本发明提供了使用该抑制剂作为抗癌剂来重新制备癌细胞凋亡（如丝氨酸蛋白酶依赖性细胞凋亡）的方法。

    IDENTIFICATION OF MODULATORS OF SERINE PROTEASE INHIBITOR KAZAL AND THEIR USE AS ANTI-CANCER AND ANTI-VIRAL AGENTS
    7.
    发明申请
    IDENTIFICATION OF MODULATORS OF SERINE PROTEASE INHIBITOR KAZAL AND THEIR USE AS ANTI-CANCER AND ANTI-VIRAL AGENTS 失效
    丝氨酸蛋白酶抑制剂KAZAL调节剂的鉴定及其作为抗癌剂和抗病毒剂的用途

    公开(公告)号：US20090017457A1

    公开(公告)日：2009-01-15

    申请号：US12065840

    申请日：2006-09-07

    Applicant: Xuanyong Lu ,  Timothy Block

    Inventor： Xuanyong Lu ,  Timothy Block

    IPC: C12Q1/68 ,  G01N33/573 ,  C07H21/02 ,  C12Q1/37 ,  C12Q1/02

    CPC classification number: C12Q1/37 ,  G01N2333/96433 ,  G01N2500/02

    Abstract: This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

    Abstract translation: 本发明描述了癌症的相关病因和新型抗癌治疗策略，基于以下发现：称为丝氨酸蛋白酶抑制剂（SPIK / SPINK / PSTI）的蛋白质被乙型和丙型肝炎病毒感染上调，从而抑制细胞 凋亡。 因此，本发明提供了SPIK抑制剂和/或抑制细胞中SPIK过度表达的技术。 抑制剂包括：1）可抑制SPIK转录物，蛋白质活性和基因表达的化合物，2）SPIK siRNA（SPIK的RNAi基因沉默或dsRNA，3）DNA反义和抗SPIK抗体。 此外，本发明提供了使用该抑制剂作为抗癌剂来重新制备癌细胞凋亡（如丝氨酸蛋白酶依赖性细胞凋亡）的方法。

    Method and system for filtering inter-node communication in a data processing system
    8.
    发明申请
    Method and system for filtering inter-node communication in a data processing system 失效

    公开(公告)号：US20050025121A1

    公开(公告)日：2005-02-03

    申请号：US10933598

    申请日：2004-09-03

    Applicant: Timothy Block ,  Richard Booth ,  David Engebretsen ,  Thomas Sand ,  Kenneth Valk

    Inventor： Timothy Block ,  Richard Booth ,  David Engebretsen ,  Thomas Sand ,  Kenneth Valk

    IPC: H04L12/56 ,  H04L12/28

    CPC classification number: H04L49/351 ,  H04L49/3009

    Abstract: A method and system for communication in a system area network (SAN) data processing system are described. The SAN includes a plurality of interconnected nodes that each have at least one port for communication. To avoid communication-induced errors that may arise, for example, if multiple nodes share the same node ID, the port of a node in the SAN is marked as “fenced” to prevent transmission of packets of a first traffic type while permitting transmission of packets of a second traffic type. The marking of the port may be recorded, for example, in a configuration register of the port. While the port is fenced, only packets of other than the first traffic type are routed via the port. In one preferred embodiment, the second traffic type represents SAN configuration traffic, and the first traffic type represents non-configuration traffic. In this preferred embodiment, the marking of the port may be removed following communication of configuration traffic utilized to negotiate unique node ID throughout the SAN.

    Methods for ultrasensitive detection and quantification of mutant hepatitis B viruses
    9.
    发明申请
    Methods for ultrasensitive detection and quantification of mutant hepatitis B viruses 审中-公开
    突变乙型肝炎病毒的超敏感检测和定量方法

    公开(公告)号：US20110053141A1

    公开(公告)日：2011-03-03

    申请号：US12862545

    申请日：2010-08-24

    Applicant: Xiangdong Ren ,  Timothy Block ,  Hui Nie

    Inventor： Xiangdong Ren ,  Timothy Block ,  Hui Nie

    IPC: C12Q1/70

    CPC classification number: C12Q1/706 ,  C12Q1/6858 ,  C12Q2561/101

    Abstract: This invention provides compositions and methods for ultrasensitive detection and quantification of mutant hepatitis B viruses (HBV). The compositions and methods of the invention can be used to detect HBV mutations for diagnostic and prognostic purposes. This invention also provides new application of a TaqMan hydrolysis probe in asymmetric real time PCR and melting curve analysis.

    Abstract translation: 本发明提供了突变乙型肝炎病毒（HBV）的超敏感检测和定量的组合物和方法。 本发明的组合物和方法可用于检测用于诊断和预后目的的HBV突变。 本发明还提供了TaqMan水解探针在不对称实时PCR和熔解曲线分析中的新应用。

Patent Agency Ranking